NJH395X
Total Payments
$155,812
Transactions
4
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $22,297 | 1 | 0 |
| 2019 | $133,415 | 2 | 0 |
| 2018 | $100.00 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $155,812 | 4 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE I MULTI CENTER OPEN LABEL DOSE FINDING STUDY OF NJH395 ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH HER2 POSITIVE ADVANCED MALIGNANCIES | Novartis Pharmaceuticals Corporation | $155,812 | 0 |
Top Doctors Receiving Payments for NJH395X
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Austin, TX | $155,812 | 4 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $155,812
Product Information
- Type Drug
- Total Payments $155,812
- Total Doctors 0
- Transactions 4
About NJH395X
NJH395X is a drug associated with $155,812 in payments to 0 healthcare providers, recorded across 4 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2018 to 2020. In 2020, $22,297 was paid across 1 transactions to 0 doctors.
The most common payment nature for NJH395X is "Unspecified" ($155,812, 100.0% of total).
NJH395X is associated with 1 research study, including "A PHASE I MULTI CENTER OPEN LABEL DOSE FINDING STUDY OF NJH395 ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH HER2 POSITIVE ADVANCED MALIGNANCIES" ($155,812).